Agilon Health AGL Restricted Cash Equivalents Current
Restricted Cash Equivalents Current at other companies
Other financials
Where this comes from
Reported directly by Agilon Health in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsCurrent.
The official record: Agilon Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agilon Health's restricted cash equivalents current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agilon Health's restricted cash equivalents current?
- Agilon Health (AGL) reported restricted cash equivalents current of $71.58M in Q1 2026.
- How has Agilon Health's restricted cash equivalents current changed year-over-year?
- Agilon Health's restricted cash equivalents current increased by 4155.6% year-over-year, from $1.68M to $71.58M.
- What is the long-term trend for Agilon Health's restricted cash equivalents current?
- Over 5 years (2020 to 2025), Agilon Health's restricted cash equivalents current has grown at a -100.0% compound annual growth rate (CAGR), from $28.38M to $0.
- What does restricted cash equivalents current mean?
- This represents cash and cash equivalents that are legally or contractually restricted from being used for general corporate purposes within the next twelve months. These funds are typically held to satisfy specific regulatory requirements, collateral obligations, or escrow agreements related to healthcare operations. Monitoring this balance is essential for assessing the company's true liquidity and the portion of cash that is unavailable for immediate operational needs.